Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, 11942, Jordan; Division of Nuclear Medicine/Department of Radiology and Nuclear Medicine, University of Jordan, Amman, 11942, Jordan.
Chrysalium Consulting, Lalaye, France; MEDraysintell, Louvain-la-Neuve, Oncidium Foundation, Mont-Saint-Guibert, Belgium; Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, 11942, Jordan.
Semin Nucl Med. 2024 Jul;54(4):622-633. doi: 10.1053/j.semnuclmed.2024.02.003. Epub 2024 Mar 13.
Radiotheranostics, a combination of diagnostic and therapeutic approaches, was first utilized in cancer management using radiopharmaceuticals to both image and selectively treat specific cancer subtypes nearly a century ago. Radiotheranostic strategies rooted in nuclear medicine have revolutionized the treatment landscape for individuals diagnosed with prostate cancer and neuroendocrine tumors in the past 10 years. In specific contexts, these approaches have emerged as the prevailing standard, yielding numerous positive results. The field of radiotheranostics shows great potential for future clinical applications. This article aims to examine the key factors that will contribute to the success of radiotheranostics in the future, as well as the current challenges and potential strategies to overcome them, with insight into the global radiotheranostic market.
放射性诊断与治疗，是诊断与治疗方法的结合，近一个世纪前，首次使用放射性药物在癌症管理中进行应用，以对特定的癌症亚型进行成像和选择性治疗。源于核医学的放射性诊断治疗策略在过去十年中彻底改变了前列腺癌和神经内分泌肿瘤患者的治疗格局。在特定情况下，这些方法已成为主流标准，取得了众多积极成果。放射性诊断治疗领域具有广阔的未来临床应用前景。本文旨在探讨未来放射性诊断治疗成功的关键因素，以及当前面临的挑战和潜在的应对策略，并深入了解全球放射性诊断治疗市场。
